Navigation Links
Penn researchers successfully alleviate pulmonary inflammation with targeted drug delivery

(PHILADELPHIA) Pulmonary inflammation can cause shallow breathing and the lungs to become brittle in patients who experience multiple blood transfusions, sepsis, lung surgery and acute lung trauma. This complication can leave patients on ventilators, which can further traumatize the lungs, and often results in a mortality rate of 30 to 40 percent. To date, no medication has been successful at preventing or mitigating the damage caused by lung inflammation. Now, a multidisciplinary research team led by David Eckmann, MD, PhD, Horatio C. Wood Professor of Anesthesiology and Critical Care at the Perelman School of Medicine at the University of Pennsylvania and professor of Bioengineering in Penn's School of Engineering and Applied Science, has found that when delivered by a microscopic transporter called a nanocarrier, steroids can access the hard-to-reach lung endothelial cells that need it most and are successful at preventing inflammation in mice. This proof-of-concept study is published in PLOS One.

"This is a treatment that benefits entirely from targeted delivery or it tends not to have any significant therapeutic benefit," says Eckmann.

"That's part of the challenge with this disorder: we have been uncertain to this point whether it was the medication or its delivery mechanism that wasn't working. Our results in mouse models show beyond a shadow of a doubt that the drugs can be effective, we just needed to improve delivery," says Eckmann. Acute lung injury develops as a result of direct or indirect trauma to the lungs. It compromises the hard-to-reach pores that enable gas exchange between the epithelial and endothelial barriers in the lungs.

During the past year the team was awarded an National Science Foundation and two NIH grants to design nanocarriers for targeted drug delivery through a combination of computer modeling and laboratory experiments. This study represents the first of their experimental results.

The team used a nanogel, a specialized nanocarrier, for drug delivery made up of two moleculesdextran (a sugar) and lysozyme (a protein)which mesh into a spaghetti-like ball that can fill with water to expand and contract. A specific lung-targeting molecule is attached to the carrier's surface and the steriod, dexamethasone, an anti-inflammatory, is loaded into the nanogel, which then binds to lung endothelial cells lining the inside wall of the blood vessels where it rapidly delivers the drug.

"This molecule on the surface of the nanocarrier has specialized preference for the lung to enhance localized and targeted drug delivery," says Eckmann.

The team next plans to try the therapy in a cohort of patients at the Hospital of the University of Pennsylvania.


Contact: Lee-Ann Donegan
University of Pennsylvania School of Medicine

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
3. Multidisciplinary team of researchers develop world’s lightest material
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
6. UCLA researchers demonstrate fully printed carbon nanotube transistor circuits for displays
7. Penn and Brown researchers demonstrate earthquake friction effect at the nanoscale
8. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
9. Researchers develop one of the worlds smallest electronic circuits
10. MU researchers identify key plant immune response in fight against bacteria
11. Researchers realize high-power, narrowband terahertz source at room temperature
Post Your Comments:
Related Image:
Penn researchers successfully alleviate pulmonary inflammation with targeted drug delivery
(Date:12/1/2015)... Va. , Dec. 1, 2015 Oxford ... senior debt to life sciences and healthcare services companies, ... secured term loan with MDRejuvena, Inc. ("the Company"). Proceeds ... and continued development of the Company,s Rejuvaphyl™ and daily ... Rejuvaphyl is the MDRejuvena brand of high potency ...
(Date:12/1/2015)... ... 01, 2015 , ... RURO, Inc., a leading LIMS, and ... colony management software solution, ezColony®, is now available as a subscription-based, cloud-hosted software ... , Many organizations are moving to cloud-hosting for LIMS and other ...
(Date:12/1/2015)... ... December 01, 2015 , ... The American Society of Gynecologic ... Kyle Mathews will join fellow surgeons in the shared pursuit of “advancing ... experienced urogynecologist, founder of Plano Urogynecology Associates and Fellow of the American ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem ... is operated by a world-class team of qualified medical researchers and practitioners, experienced ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., a ... to mobile and PC devices, announced its ActiveIRIS® technology ... arrows NX F-02H launched by NTT DOCOMO, INC in ... is the second smartphone to include iris recognition technology, ... ARROWS NX F-04G in May 2015, world,s first smartphone ...
Breaking Biology News(10 mins):